Agenda

Welcome Day

Thursday, 2/20/25

6:00 PM - 9:00 PM

Poster Session & Welcome Reception

Day One

Friday, 2/21/25

Breakfast Symposium (Non-CE)

The Evolving Standard of Care in Treating Newly Diagnosed Hematologic Malignancies: PART 1

• 1L CLL
• Indolent Lymphomas
• Aggressive Lymphomas
• Hodgkin’s
• Community Application
• Q&A

Networking Break

The Evolving Standard of Care in Treating Newly Diagnosed Hematologic Malignancies: PART 2

• 1L MPNs+MDS
• AML +ALL
• NDMM
• Debate: Is transplant still the best option for all eligible patients?
• Community Application MM
• Q&A

Lunch Symposium (Non-CE)

Treating Relapse after Initial Therapy: PART 1

• MM Early Relapse
• Should CART be used for 2nd line therapy?
• MPNs
• MDS
• Community Application
• Q&A

Networking Break

Treating Relapse after Initial Therapy: PART 2

• Optimal Sequencing in CLL
• Indolent Lymphomas
• Hodgkins
• Aggressive Lymphomas
• Community Application
• Q&A

Keynote Speaker (Non-CE)

Day Two

Saturday, 2/22/25

Breakfast Symposium (Non-CE)

Translating T-Cell redirecting Therapies into the Community

• Managing CRS in the Community
• Managing neurotoxicity in the community
• Preventing and Managing Infections
• Integrating Bispecifics into Practice
• Q&A

Networking Break

Treating Later Relapse: 3L and Beyond

• RRMM 3L+
• Debate: Later Relapse in MM: CAR-T vs. Bispecifics 
• Indolent Lymphomas (including CLL)
• Aggressive Lymphomas
• Community Application
• Q&A

Lunch Symposium (Non-CE)

Hot Topics in Hematology

• Health Policy
• MRD in Hematologic Malignancies
• Defining high risk disease in hematologic malignancies
• Dealing with Drug Shortages in Oncology
• DEI in Heme Malignancies
• Q&A

Networking Break

The Evolving Treatment Landscape Across Hematologic Malignancies: What's on the horizon?

• Multiple Myeloma
• CLL
• Indolent Lymphomas
• Aggressive Lymphomas
• MPNs+ MDS
• AML + ALL

Farewell Reception